Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
I-Mab Biopharma US Limited
Sun Yat-sen University
National Cancer Institute, Naples
Centre Hospitalier Universitaire de Besancon
Servier
Federation Francophone de Cancerologie Digestive
ETOP IBCSG Partners Foundation
Harbin Medical University
H. Lee Moffitt Cancer Center and Research Institute
Fudan University
Universitätsklinikum Hamburg-Eppendorf
Fudan University
Fox Chase Cancer Center
University of Kansas Medical Center
Odonate Therapeutics, Inc.
AIO-Studien-gGmbH
Novartis
Herlev Hospital
University of Florida
The University of Hong Kong
NYU Langone Health
Asan Medical Center
International Group of Endovascular Oncology
University Health Network, Toronto
Puma Biotechnology, Inc.
Dong-A University Hospital
NYU Langone Health
University of California, Davis
Peking University
Samsung Medical Center
ARCAGY/ GINECO GROUP
GlaxoSmithKline
HaEmek Medical Center, Israel
Duke University
Vejle Hospital
University of Chicago
Fudan University
AIO-Studien-gGmbH
Accelerated Community Oncology Research Network
UNICANCER
SWOG Cancer Research Network
M.D. Anderson Cancer Center
Tragara Pharmaceuticals, Inc.
Fudan University
ARCAGY/ GINECO GROUP
Croatian Cooperative Group for Clinical Research in Oncology
South Eastern European Research Oncology Group
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute